Caris Life Sciences (CAI) Profit After Tax (2024 - 2026)

Caris Life Sciences' Profit After Tax history runs 3 years deep, the most recent figure standing at -$510000.0 for Q1 2026.

• In Q1 2026, Profit After Tax rose 99.5% year-over-year to -$510000.0; the TTM figure through Mar 2026 stood at -$411.4 million (down 50.46% YoY), while the FY2025 annual figure was -$68.1 million, up 75.85% from the prior year.
• Profit After Tax for Q1 2026 stood at -$510000.0, down from $82.0 million in the prior quarter.
• The five-year high for Profit After Tax was $82.0 million in Q4 2025, with the low at -$517.2 million in Q2 2025.
• The 3-year median for Profit After Tax is -$51.5 million (2024), against an average of -$85.6 million.
• Peak annual rise in Profit After Tax reached 321.78% in 2025, while the deepest fall reached 682.52% in 2025.
• Caris Life Sciences' Profit After Tax stood at -$37.0 million in 2024, then jumped by 321.78% to $82.0 million in 2025, then plunged by 100.62% to -$510000.0 in 2026.
• Business Quant data shows CAI's Profit After Tax at -$510000.0 in Q1 2026, $82.0 million in Q4 2025, and $24.3 million in Q3 2025.